 |
|
MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
Ying Wang, Shengfeng Wang, Xiude Fan, Jiajun Zhao, Yongfeng Song
Clin Mol Hepatol. 2025;31(2):e128-e133. Published online 2024 Dec 26 DOI: https://doi.org/10.3350/cmh.2024.1008
|
|
Citations to this article as recorded by
 Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: a cross-sectional study of NHANES 2017–2020
Xin Qiu, Shuang Shen, Nizhen Jiang, Yifei Feng, Guodong Yang, Donghong Lu
BMC Gastroenterology.2025;[Epub] CrossRef
|